Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.

Brady AM, Walter EB, Markowitz LE, Unger ER, Panicker G.

Hum Vaccin Immunother. 2020 Jan 22:1-6. doi: 10.1080/21645515.2019.1706410. [Epub ahead of print]

PMID:
31967933
2.

Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination.

Naleway AL, Crane B, Smith N, Francisco M, Weinmann S, Markowitz LE.

Sex Transm Dis. 2019 Dec 26. doi: 10.1097/OLQ.0000000000001103. [Epub ahead of print]

PMID:
31880738
3.

Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States.

Laprise JF, Chesson HW, Markowitz LE, Drolet M, Martin D, Bénard É, Brisson M.

Ann Intern Med. 2019 Dec 10. doi: 10.7326/M19-1182. [Epub ahead of print]

PMID:
31816629
4.

Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses.

Markowitz LE, Naleway AL, Klein NP, Lewis RM, Crane B, Querec TD, Hsiao A, Aukes L, Timbol J, Weinmann S, Liu G, Steinau M, Unger ER.

J Infect Dis. 2019 Nov 30. pii: jiz555. doi: 10.1093/infdis/jiz555. [Epub ahead of print]

PMID:
31784749
5.

Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices.

Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE.

Am J Transplant. 2019 Nov;19(11):3202-3206. doi: 10.1111/ajt.15633. No abstract available.

PMID:
31742913
6.

Effectiveness of 1, 2, AND 3 Human Papillomavirus Vaccine doses against HPV-16/18 positive High-grade Cervical Lesions.

Johnson Jones ML, Gargano JW, Powell M, Park IU, Niccolai LM, Bennett NM, Griffin MR, Querec T, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

Am J Epidemiol. 2019 Nov 4. pii: kwz253. doi: 10.1093/aje/kwz253. [Epub ahead of print]

PMID:
31680146
7.

Trends in human papillomavirus (HPV) vaccination initiation among adolescents aged 13-17 by metropolitan statistical area (MSA) status, National Immunization Survey - Teen, 2013 - 2017.

Walker TY, Elam-Evans LD, Williams CL, Fredua B, Yankey D, Markowitz LE, Stokley S.

Hum Vaccin Immunother. 2019 Oct 29:1-8. doi: 10.1080/21645515.2019.1671765. [Epub ahead of print]

PMID:
31662024
8.

HPV Vaccine Delivery Practices by Primary Care Physicians.

Kempe A, O'Leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, Beaty BL, Meites E, Stokley S, Lindley MC.

Pediatrics. 2019 Oct;144(4). pii: e20191475. doi: 10.1542/peds.2019-1475. Epub 2019 Sep 16.

PMID:
31527175
9.

Transgender Women Have Higher Human Papillomavirus Prevalence Than Men Who Have Sex With Men-Two U.S. Cities, 2012-2014.

Singh V, Gratzer B, Gorbach PM, Crosby RA, Panicker G, Steinau M, Amiling R, Unger ER, Markowitz LE, Meites E.

Sex Transm Dis. 2019 Oct;46(10):657-662. doi: 10.1097/OLQ.0000000000001051.

PMID:
31517805
10.

Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey.

McClung NM, Lewis RM, Gargano JW, Querec T, Unger ER, Markowitz LE.

J Adolesc Health. 2019 Dec;65(6):715-722. doi: 10.1016/j.jadohealth.2019.07.003. Epub 2019 Sep 9.

PMID:
31515134
11.

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018.

Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, Singleton JA, Stokley S.

MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):718-723. doi: 10.15585/mmwr.mm6833a2.

12.

Human Papillomavirus-Attributable Cancers - United States, 2012-2016.

Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M.

MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724-728. doi: 10.15585/mmwr.mm6833a3.

13.

Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.

Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE.

MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. doi: 10.15585/mmwr.mm6832a3.

14.

Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.

Markowitz LE, Naleway AL, Lewis RM, Crane B, Querec TD, Weinmann S, Steinau M, Unger ER.

Vaccine. 2019 Jun 27;37(29):3918-3924. doi: 10.1016/j.vaccine.2019.04.099. Epub 2019 May 31.

PMID:
31160099
15.

Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States.

Chesson HW, Meites E, Ekwueme DU, Saraiya M, Markowitz LE.

Hum Vaccin Immunother. 2019;15(7-8):1942-1948. doi: 10.1080/21645515.2019.1603562. Epub 2019 May 20.

PMID:
31107640
16.

Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.

McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, Bennett NM, Scahill M, Niccolai LM, Brackney M, Griffin MR, Pemmaraju M, Querec TD, Cleveland AA, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):337-343. doi: 10.15585/mmwr.mm6815a1.

17.

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006-2014: The impact of human papillomavirus vaccination.

Shing JZ, Hull PC, Zhu Y, Gargano JW, Markowitz LE, Cleveland AA, Pemmaraju M, Park IU, Whitney E, Mitchel EF, Griffin MR.

Papillomavirus Res. 2019 Jun;7:141-149. doi: 10.1016/j.pvr.2019.04.007. Epub 2019 Apr 10.

18.

Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.

Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Saadeh K, Pemmaraju M, Higgins K, Ehlers S, Scahill M, Johnson Jones ML, Querec T, Markowitz LE, Unger ER; HPV-IMPACT Working Group.

Int J Cancer. 2020 Feb 1;146(3):810-818. doi: 10.1002/ijc.32340. Epub 2019 May 6.

PMID:
30980692
19.

Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.

McClung NM, Gargano JW, Bennett NM, Niccolai LM, Abdullah N, Griffin MR, Park IU, Cleveland AA, Querec TD, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):602-609. doi: 10.1158/1055-9965.EPI-18-0885. Epub 2019 Feb 21.

PMID:
30792242
20.

Increasing human papillomavirus vaccination at the recommended age.

Lin X, Shrader L, Rodgers L, Stokley S, Markowitz LE.

Vaccine. 2019 Jan 29;37(5):686-689. doi: 10.1016/j.vaccine.2018.12.023. Epub 2018 Dec 24.

PMID:
30591254
21.

Seroprevalence of Human Papillomavirus 6/11/16/18 Among Self-identified Gay/Bisexual Men Who Have Sex With Men, Men Who Have Sex With Women, and Females, United States, 2003-2010.

Lewis RM, Markowitz LE, Panicker G, Unger ER.

Clin Infect Dis. 2019 Aug 30;69(6):1011-1018. doi: 10.1093/cid/ciy1002.

PMID:
30475987
22.

Association of Provider Recommendation and Human Papillomavirus Vaccination Initiation among Male Adolescents Aged 13-17 Years-United States.

Lu PJ, Yankey D, Fredua B, O'Halloran AC, Williams C, Markowitz LE, Elam-Evans LD.

J Pediatr. 2019 Mar;206:33-41.e1. doi: 10.1016/j.jpeds.2018.10.034. Epub 2018 Nov 15.

23.

Risk Factors for Oral Human Papillomavirus Infection Among Young Men Who Have Sex With Men-2 Cities, United States, 2012-2014.

Oliver SE, Gorbach PM, Gratzer B, Steinau M, Collins T, Parrish A, Kerndt PR, Crosby RA, Unger ER, Markowitz LE, Meites E.

Sex Transm Dis. 2018 Oct;45(10):660-665. doi: 10.1097/OLQ.0000000000000845.

24.

Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015.

Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB.

MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):918-924. doi: 10.15585/mmwr.mm6733a2.

25.

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017.

Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, Fredua B, Stokley S.

MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917. doi: 10.15585/mmwr.mm6733a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1164.

26.

Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.

Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Johnson Jones ML, Whitney E, Pemmaraju M, Brackney M, Abdullah N, Scahill M, Dahl RM, Cleveland AA, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

Clin Infect Dis. 2019 Apr 8;68(8):1282-1291. doi: 10.1093/cid/ciy707.

27.

Disclosure of Sexual Behavior Is Significantly Associated With Receiving a Panel of Health Care Services Recommended for Men Who Have Sex With Men.

Singh V, Crosby RA, Gratzer B, Gorbach PM, Markowitz LE, Meites E.

Sex Transm Dis. 2018 Dec;45(12):803-807. doi: 10.1097/OLQ.0000000000000886.

PMID:
29944645
28.

Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.

Chesson HW, Meites E, Ekwueme DU, Saraiya M, Markowitz LE.

Vaccine. 2018 Jul 5;36(29):4362-4368. doi: 10.1016/j.vaccine.2018.04.071.

29.

Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.

Markowitz LE, Drolet M, Perez N, Jit M, Brisson M.

Vaccine. 2018 Aug 6;36(32 Pt A):4806-4815. doi: 10.1016/j.vaccine.2018.01.057. Epub 2018 May 22. Review.

30.

Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era.

Oakley F, Desouki MM, Pemmaraju M, Gargano JM, Markowitz LE, Steinau M, Unger ER, Zhu Y, Fadare O, Griffin MR.

Am J Prev Med. 2018 Jul;55(1):19-25. doi: 10.1016/j.amepre.2018.03.015. Epub 2018 May 16.

PMID:
29778314
31.

Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007-2014.

Gargano JW, Zhou F, Stokley S, Markowitz LE.

Vaccine. 2018 May 31;36(23):3381-3386. doi: 10.1016/j.vaccine.2018.03.045. Epub 2018 May 4.

PMID:
29735321
32.

Seroprevalence of Herpes Simplex Virus Types 1 and 2 Among Pregnant Women and Sexually Active, Nonpregnant Women in the United States.

Patton ME, Bernstein K, Liu G, Zaidi A, Markowitz LE.

Clin Infect Dis. 2018 Oct 30;67(10):1535-1542. doi: 10.1093/cid/ciy318.

33.

Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016.

Lewis RM, Markowitz LE.

Vaccine. 2018 May 3;36(19):2567-2573. doi: 10.1016/j.vaccine.2018.03.083. Epub 2018 Apr 9.

34.

Ten Years of Human Papillomavirus Vaccination in the United States.

Markowitz LE, Gee J, Chesson H, Stokley S.

Acad Pediatr. 2018 Mar;18(2S):S3-S10. doi: 10.1016/j.acap.2017.09.014. Review.

PMID:
29502635
35.

Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.

Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT.

Vaccine. 2018 Mar 20;36(13):1781-1788. doi: 10.1016/j.vaccine.2018.02.034. Epub 2018 Feb 21.

PMID:
29477308
36.

Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14-59 Years, United States, 2013-2014.

Lewis RM, Markowitz LE, Gargano JW, Steinau M, Unger ER.

J Infect Dis. 2018 Mar 5;217(6):869-877. doi: 10.1093/infdis/jix655.

37.

CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide.

Senkomago V, Duran D, Loharikar A, Hyde TB, Markowitz LE, Unger ER, Saraiya M.

Emerg Infect Dis. 2017 Dec;23(13). doi: 10.3201/eid2313.170603. Review.

38.

Monitoring the impact of HPV vaccine in males-Considerations and challenges.

Brotherton JML, Giuliano AR, Markowitz LE, Dunne EF, Ogilvie GS.

Papillomavirus Res. 2016 Dec;2:106-111. doi: 10.1016/j.pvr.2016.05.001. Epub 2016 May 17.

39.

Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.

Oliver SE, Unger ER, Lewis R, McDaniel D, Gargano JW, Steinau M, Markowitz LE.

J Infect Dis. 2017 Sep 1;216(5):594-603. doi: 10.1093/infdis/jix244.

40.

Human papillomavirus vaccination coverage using two-dose or three-dose schedule criteria.

Lin X, Rodgers L, Zhu L, Stokley S, Meites E, Markowitz LE.

Vaccine. 2017 Oct 13;35(43):5759-5761. doi: 10.1016/j.vaccine.2017.08.090. Epub 2017 Sep 8.

41.

Cervical Cancer Screening and Prevention in 78 Sexually Transmitted Disease Clinics-United States, 2014-2015.

McGinnis E, Meyerson BE, Meites E, Saraiya M, Griesse R, Snoek E, Haderxhanaj L, Markowitz LE, Smith W.

Sex Transm Dis. 2017 Oct;44(10):637-641. doi: 10.1097/OLQ.0000000000000659.

42.

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2016.

Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, Williams CL, Meyer SA, Stokley S.

MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882. doi: 10.15585/mmwr.mm6633a2.

43.

Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States.

Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, Newcomer SR, Tolsma D, Markowitz LE.

Am J Epidemiol. 2018 Feb 1;187(2):298-305. doi: 10.1093/aje/kwx253.

PMID:
28641366
44.

Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men and Transgender Women in 2 US Cities, 2012-2014.

Gorbach PM, Cook R, Gratzer B, Collins T, Parrish A, Moore J, Kerndt PR, Crosby RA, Markowitz LE, Meites E.

Sex Transm Dis. 2017 Jul;44(7):436-441. doi: 10.1097/OLQ.0000000000000626.

45.

Increasing Human Papillomavirus Vaccine Coverage Among Men Who Have Sex With Men-National HIV Behavioral Surveillance, United States, 2014.

Oliver SE, Hoots BE, Paz-Bailey G, Markowitz LE, Meites E; NHBS Study Group.

J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S370-S374. doi: 10.1097/QAI.0000000000001413.

46.

Population-attributable fraction of tubal factor infertility associated with chlamydia.

Gorwitz RJ, Wiesenfeld HC, Chen PL, Hammond KR, Sereday KA, Haggerty CL, Johnson RE, Papp JR, Kissin DM, Henning TC, Hook EW 3rd, Steinkampf MP, Markowitz LE, Geisler WM.

Am J Obstet Gynecol. 2017 Sep;217(3):336.e1-336.e16. doi: 10.1016/j.ajog.2017.05.026. Epub 2017 May 19.

47.

Concordance Between Anal and Oral Human Papillomavirus Infections Among Young Men Who have Sex With Men.

Steinau M, Gorbach P, Gratzer B, Braxton J, Kerndt PR, Crosby RA, Unger ER, Markowitz LE, Meites E.

J Infect Dis. 2017 Jun 15;215(12):1832-1835. doi: 10.1093/infdis/jix232.

PMID:
28505338
48.

Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.

Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, Rodriguez-Lainz A, Fiebelkorn AP.

MMWR Surveill Summ. 2017 May 5;66(11):1-28. doi: 10.15585/mmwr.ss6611a1.

49.

Prevalence of HPV in Adults Aged 18-69: United States, 2011-2014.

McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R.

NCHS Data Brief. 2017 Apr;(280):1-8.

50.

TPrevalence of HPV in Adults Aged 18-69: United States, 2011-2014.

McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R.

NCHS Data Brief. 2017 Apr;(280):1-8.

PMID:
28437239

Supplemental Content

Loading ...
Support Center